Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 13/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.35 |
| ▸ | HTR3B | O95264 | 3/20 | 0.35 |
| ▸ | HTR3A | P46098 | 3/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880813 | 1.00 | PDE10A (0.36) | PDE10AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL23107256 | 0.81 | MAP4K1 (0.38) | PDE10AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL23103955 | 0.81 | MAP4K1 (0.38) | PDE10AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL23504098 | 0.81 | MAP4K1 (0.38) | PDE10AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL22551892 | 0.80 | HTR3A (0.38) | PDE10AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL30385235 | 0.80 | HTR3A (0.38) | PDE10AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL21730229 | 0.80 | PDE10A (0.39) | PDE10AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL30385308 | 0.80 | PDE10A (0.39) | PDE10AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL21722602 | 0.76 | HTR3A (0.60) | PDE10AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL23089658 | 0.74 | GRIN2D (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-10898481-B2 | Pyrazine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-26 | — | — | US | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10898481-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | PDE10A 278/4885HTR3E 398/4885HTR3B 298/4885 |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | PDE10A 278/4885HTR3E 398/4885HTR3B 298/4885 |
| US-11571420-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | PDE10A 278/4885HTR3E 398/4885HTR3B 298/4885 |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | PDE10A 278/4885HTR3E 398/4885HTR3B 298/4885 |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | PDE10A 278/4885HTR3E 398/4885HTR3B 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.